1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Home Healthcare Reps - General Discussion

Anonymous board for Home Healthcare Reps

Sort By:
Title
Replies Views
Last Message ↓
  1. Anonymous
    Replies:
    94
    Views:
    36,135
  2. anonymous
    Replies:
    0
    Views:
    77
  3. Anonymous
    Replies:
    10
    Views:
    20,682
  4. anonymous
    Replies:
    5
    Views:
    2,165
  5. anonymous
    Replies:
    1
    Views:
    277
  6. anonymous
    Replies:
    1
    Views:
    274
  7. Joe Moore
    Replies:
    0
    Views:
    298
  8. Anonymous
    Replies:
    16
    Views:
    5,292
  9. anonymous
    Replies:
    0
    Views:
    256
  10. anonymous
    Replies:
    1
    Views:
    340
  11. anonymous
    Replies:
    0
    Views:
    468
  12. Anonymous
    Replies:
    7
    Views:
    5,874
  13. anonymous
    Replies:
    0
    Views:
    561
  14. anonymous
    Replies:
    0
    Views:
    588
  15. anonymous
    Replies:
    0
    Views:
    603
  16. Anonymous
    Replies:
    11
    Views:
    5,308
  17. anonymous
    Replies:
    1
    Views:
    783
  18. Anonymous
    Replies:
    6
    Views:
    3,675
  19. Anonymous
    Replies:
    11
    Views:
    4,705
  20. anonymous
    Replies:
    0
    Views:
    721

Thread Display Options

Loading...